Vivani Medical (VANI) Price Target Lowered to $3.50 from $4

H.C. Wainwright analyst Yi Chen has lowered Vivani Medical's (VANI) price target to $3.50 from $4, citing an increase in the company's share count as a factor. Despite this reduction, the analyst maintains a Buy rating on the shares. This move follows the recent announcement of the company's 2025 results. The firm believes that NPM-139 may offer efficacy comparable to Wegovy with less frequent administration requirements, which could positively influence market perceptions.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.